Brookline Capital Markets Predicts Imunon Q3 Earnings

Imunon, Inc. (NASDAQ:IMNN) – Brookline Capital Markets raised their Q3 2026 EPS estimates for Imunon in a report released on Tuesday, August 11th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will post earnings of ($0.71) per share for the quarter, up from their previous forecast of ($0.74). The consensus estimate for Imunon’s current full-year earnings is ($3.46) per share. Brookline Capital Markets also issued estimates for Imunon’s Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.89) EPS, Q1 2027 earnings at ($0.78) EPS, Q2 2027 earnings at ($0.76) EPS, Q3 2027 earnings at ($0.76) EPS, Q4 2027 earnings at ($0.73) EPS and FY2027 earnings at ($3.03) EPS.

Imunon (NASDAQ:IMNN) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.33.

Several other research firms have also issued reports on IMNN. Maxim Group set a $10.00 target price on shares of Imunon and gave the stock a “buy” rating in a research note on Friday, April 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Imunon presently has an average rating of “Hold” and an average target price of $10.00.

Imunon Stock Down 1.9%

IMNN stock opened at $1.58 on Friday. The stock’s 50 day moving average is $1.79 and its 200-day moving average is $2.53. Imunon has a twelve month low of $1.47 and a twelve month high of $6.99. The firm has a market capitalization of $8.86 million, a PE ratio of -0.41 and a beta of 1.97.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Imunon stock. DRW Securities LLC boosted its position in Imunon, Inc. (NASDAQ:IMNN) by 6.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 58,830 shares of the company’s stock after acquiring an additional 3,803 shares during the period. DRW Securities LLC owned 1.92% of Imunon worth $224,000 as of its most recent SEC filing. Institutional investors own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.